272 related items for PubMed ID: 17803344
1. Ulinastatin therapy in kawasaki disease.
Iwashima S, Seguchi M, Matubayashi T, Ohzeki T.
Clin Drug Investig; 2007; 27(10):691-6. PubMed ID: 17803344
[Abstract] [Full Text] [Related]
2. [Use of the urinary trypsin inhibitor ulinastatin for acute Kawasaki disease].
Kawamura Y, Kanai T, Takeshita S, Nonoyama S.
Nihon Rinsho; 2014 Sep; 72(9):1650-3. PubMed ID: 25518417
[Abstract] [Full Text] [Related]
3. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
[Abstract] [Full Text] [Related]
4. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study.
Iwashima S, Kimura M, Ishikawa T, Ohzeki T.
Clin Drug Investig; 2011 May; 31(3):191-9. PubMed ID: 21456105
[Abstract] [Full Text] [Related]
5. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH.
PLoS One; 2015 May; 10(12):e0144603. PubMed ID: 26658843
[Abstract] [Full Text] [Related]
6. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[Abstract] [Full Text] [Related]
7. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
[Abstract] [Full Text] [Related]
8. Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: a retrospective study.
Kanai T, Ishiwata T, Kobayashi T, Sato H, Takizawa M, Kawamura Y, Tsujimoto H, Nakatani K, Ishibashi N, Nishiyama M, Hatai Y, Asano Y, Kobayashi T, Takeshita S, Nonoyama S.
Circulation; 2011 Dec 20; 124(25):2822-8. PubMed ID: 22104548
[Abstract] [Full Text] [Related]
9. [Clinical utility of ulinastatin, urinary protease inhibitor in acute Kawasaki disease].
Saji T.
Nihon Rinsho; 2008 Feb 20; 66(2):343-8. PubMed ID: 18265458
[Abstract] [Full Text] [Related]
10. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
Samadli S, Liu FF, Mammadov G, Wang JJ, Liu HH, Wu YF, Luo HH, Wu Y, Chen WX, Zhang DD, Wei W, Hu P.
Pediatr Rheumatol Online J; 2019 Jul 31; 17(1):53. PubMed ID: 31366406
[Abstract] [Full Text] [Related]
11. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM, Silverman ED, McCrindle BW, Yeung RS.
J Pediatr; 2002 Apr 31; 140(4):450-5. PubMed ID: 12006960
[Abstract] [Full Text] [Related]
12. [Glucocorticoid combined with ulinastatin in treatment of Kawasaki disease in children: a non-randomized controlled clinical trial].
Zhao DM, Yin QL, Ji XH, Haiweier M, Meng GY, Cheng QT, Ju LJ.
Zhongguo Dang Dai Er Ke Za Zhi; 2015 Aug 31; 17(8):780-5. PubMed ID: 26287338
[Abstract] [Full Text] [Related]
13. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
Manlhiot C, Yeung RS, Chahal N, McCrindle BW.
Pediatr Allergy Immunol; 2010 May 31; 21(3):515-21. PubMed ID: 20546528
[Abstract] [Full Text] [Related]
14. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
Han CL, Zhao SL.
Med Sci Monit; 2018 Oct 11; 24():7264-7270. PubMed ID: 30307902
[Abstract] [Full Text] [Related]
15. Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.
Xie T, Wang Y, Fu S, Wang W, Xie C, Zhang Y, Gong F.
Pediatr Rheumatol Online J; 2017 Mar 21; 15(1):17. PubMed ID: 28320400
[Abstract] [Full Text] [Related]
16. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
Qin LJ, Wang HW, Hu XF, Liu QJ, Shi H, Wei YX, Chen QJ, Cheng PX.
Zhonghua Er Ke Za Zhi; 2006 Dec 21; 44(12):891-5. PubMed ID: 17254453
[Abstract] [Full Text] [Related]
17. Phase II Open Label Study of Anakinra in Intravenous Immunoglobulin-Resistant Kawasaki Disease.
Koné-Paut I, Tellier S, Belot A, Brochard K, Guitton C, Marie I, Meinzer U, Cherqaoui B, Galeotti C, Boukhedouni N, Agostini H, Arditi M, Lambert V, Piedvache C.
Arthritis Rheumatol; 2021 Jan 21; 73(1):151-161. PubMed ID: 32779863
[Abstract] [Full Text] [Related]
18. Fever pattern and C-reactive protein predict response to rescue therapy in Kawasaki disease.
Nakagama Y, Inuzuka R, Hayashi T, Shindo T, Hirata Y, Shimizu N, Inatomi J, Yokoyama Y, Namai Y, Oda Y, Takamizawa M, Harita Y, Oka A.
Pediatr Int; 2016 Mar 21; 58(3):180-184. PubMed ID: 26222760
[Abstract] [Full Text] [Related]
19. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population.
Friedman KG, Gauvreau K, Hamaoka-Okamoto A, Tang A, Berry E, Tremoulet AH, Mahavadi VS, Baker A, deFerranti SD, Fulton DR, Burns JC, Newburger JW.
J Am Heart Assoc; 2016 Sep 15; 5(9):. PubMed ID: 27633390
[Abstract] [Full Text] [Related]
20. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.
Lim YJ, Jung JW.
Yonsei Med J; 2014 Sep 15; 55(5):1260-6. PubMed ID: 25048483
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
